Volume | 14,549 |
|
|||||
News | - | ||||||
Day High | 4.70 | Low High |
|||||
Day Low | 4.3238 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
NeuroBo Pharmaceuticals Inc | NRBO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
4.62 | 4.3238 | 4.70 | 4.60 | 4.66 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
180 | 14,549 | US$ 4.60 | US$ 66,915 | - | 2.8888 - 6.7499 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:20:18 | 5 | US$ 4.70 | USD |
NeuroBo Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
22.32M | 4.85M | - | 0 | -12.47M | -2.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NeuroBo Pharmaceuticals News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRBO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.02 | 4.736 | 3.95 | 4.46 | 19,750 | 0.58 | 14.43% |
1 Month | 3.26 | 4.736 | 2.99 | 3.70 | 24,784 | 1.34 | 41.10% |
3 Months | 5.35 | 6.7499 | 2.99 | 5.34 | 109,131 | -0.75 | -14.02% |
6 Months | 3.364 | 6.7499 | 2.90 | 5.33 | 711,160 | 1.24 | 36.74% |
1 Year | 4.88 | 6.7499 | 2.8888 | 5.00 | 471,426 | -0.28 | -5.74% |
3 Years | 674.40 | 1,576.80 | 2.8888 | 259.43 | 1,037,854 | -669.80 | -99.32% |
5 Years | 2,196.00 | 7,200.00 | 2.8888 | 321.59 | 742,835 | -2,191.40 | -99.79% |
NeuroBo Pharmaceuticals Description
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. |